- Home
- MIND vs ANVS Comparison
MIND vs ANVS Comparison
Compare MIND & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIND | ANVS |
|---|---|---|
| Founded | 1987 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.4M | 69.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | MIND | ANVS |
|---|---|---|
| Price | $6.66 | $1.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 104.4K | ★ 1.2M |
| Earning Date | 04-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.31 | N/A |
| Revenue Next Year | $1.01 | N/A |
| P/E Ratio | $22.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.51 | $1.54 |
| 52 Week High | $14.50 | $5.50 |
Technical Indicators
Market Signals| Indicator | MIND | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 44.92 | 41.81 |
| Support Level | $6.50 | $1.79 |
| Resistance Level | $6.76 | $2.38 |
| Average True Range (ATR) | 0.31 | 0.16 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 20.37 | 16.54 |
Price Performance
Historical ComparisonAbout MIND MIND Technology Inc. (DE)
MIND Technology Inc provides technology and solutions for exploration, survey, and defense applications in oceanographic, hydrographic, defense, seismic, and security industries. The company operates in segments namely, Seamap Marine Products and Klein Marine Products helps manufacture and sell specialized, high-performance sonar and seismic equipment. The company generates more revenue from Seamap Marine Products. The company's geographical segments include the United States; China, Norway; Turkey; Singapore; and Canada & Other.
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.